Related Experiment Video
Updated: Jun 17, 2026

Assessment of the Metabolic Effects of Isocaloric 2:1 Intermittent Fasting in Mice
Published on: November 27, 2019
Dietary Protein Reduction During Isocaloric Conditions Reduces Body Weight in Men With Overweight or Obesity
Aslak E Lyster1,2, Amalie S Frederiksen1,2, Jacob K Jensen1
1The August Krogh Section for Human and Molecular Physiology, Department of Nutrition, Exercise and Sports, Faculty of Science, University of Copenhagen, Copenhagen, Denmark.
Objective:
Dietary protein reduction increases plasma fibroblast growth factor 21 (FGF21) and energy requirements in lean men under eucaloric conditions. Whether these metabolic effects translate to weight loss during isocaloric conditions in men with overweight or obesity remains unclear.
Methods:
Seventeen men with overweight or obesity were randomly allocated to two different highly controlled, isocaloric diets for 5 weeks, receiving either a protein-reduced diet (0.9 g kg-1 BW day-1) substituted with increased carbohydrates or a habitual diet (1.8 g kg-1 BW day-1).
Results:
Protein reduction induced a 2.0 ± 0.6 kg weight loss and increased plasma FGF21 concentration compared with higher protein intake, without caloric restriction. Changes in plasma FGF21 concentration were inversely associated with changes in body weight (r = -0.59, p = 0.02). Expression of key components in the FGF21 receptor complex, FGFR1 and β-klotho, and downstream targets in subcutaneous adipose tissue remained unchanged. Markers of skeletal muscle mitochondrial oxidative phosphorylation were also unaltered. Fat mass decreased significantly, whereas this level of protein reduction only tended to lower lean body mass.
Conclusions:
These findings suggest that reducing protein intake (0.9 g kg-1 BW day-1), substituted with increased carbohydrates, compared with a habitual protein intake (1.8 g kg-1 BW day-1), can induce weight loss without restricting total energy intake in men with overweight or obesity.
Trial Registration:
ClinicalTrials.gov identifier: NCT06263725.
Related Concept Videos
Drug Dosing: Obese Patients
Atherosclerosis III: Management
Chronic Kidney Disease III: Interprofessional Care
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Obesity

